{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:59:21Z","timestamp":1786118361926,"version":"build-2736575974"},"reference-count":98,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Recent data suggest that sodium\u2013glucose cotransporter 2 inhibitors have cardioprotective benefits. This effect may extend towards cardioprotection in cancer therapy-related cardiac dysfunction, with proposed mechanisms extending beyond glycemic control to include anti-inflammatory effects, oxidative stress reduction, and metabolic reprogramming. This review synthesizes potential mechanisms, observational data, and emerging trial evidence to support sodium\u2013glucose cotransporter 2 inhibitors as a primary prevention strategy for cancer therapy-related cardiac dysfunction, particularly in anthracycline-exposed populations.<\/jats:p>","DOI":"10.15420\/usc.2025.20","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:29:20Z","timestamp":1785760160000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Hyperglycemia: The Role of Sodium\u2013Glucose Cotransporter\u00a02 Inhibitors in Cancer Treatment-related Cardiac Dysfunction"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-626X","authenticated-orcid":false,"given":"Rebecca S","family":"Steinberg","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00py81415","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5918-5136","authenticated-orcid":false,"given":"Ritika","family":"Tuli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02gy6qp39","id-type":"ROR","asserted-by":"publisher"}],"name":"Allegheny General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-1795","authenticated-orcid":false,"given":"Shivani","family":"Reddy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03nxfhe13","id-type":"ROR","asserted-by":"publisher"}],"name":"Baylor University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-9468","authenticated-orcid":false,"given":"Rafael","family":"Toro-Manotas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/014ye1258","id-type":"ROR","asserted-by":"publisher"}],"name":"Rutgers New Jersey Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1938-9679","authenticated-orcid":false,"given":"Natalie","family":"Marrero","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02y070a55","id-type":"ROR","asserted-by":"publisher"}],"name":"Jackson Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu V","family":"Balanescu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu Murali","family":"Mysore","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04rq5mt64","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Rakisheva A, Farmakis D, Attanasio A, et al. Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A clinical consensus statement of the Heart Failure Association, the European association of preventive cardiology of the ESC, and the ESC Council of Cardio-Oncology. Eur J Heart Fail 2025;27:2084\u201399. https:\/\/doi.org\/10.1002\/ejhf.3753; PMID: 40679941. DOI: 10.1002\/ejhf.3753","DOI":"10.1002\/ejhf.3753"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211; PMID: 27567406. DOI: 10.1093\/eurheartj\/ehw211","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Deng HW, Fan R, Zhai YS, et al. Incidence of chemotherapy-related cardiac dysfunction in cancer patients. Clin Cardiol 2024;47:e24269. https:\/\/doi.org\/10.1002\/clc.24269; PMID: 38634453. DOI: 10.1002\/clc.24269","DOI":"10.1002\/clc.24269"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900\u20132. https:\/\/doi.org\/10.1200\/JCO.2005.05.827; PMID: 15860848. DOI: 10.1200\/JCO.2005.05.827","DOI":"10.1200\/JCO.2005.05.827"},{"key":"ref4","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244; PMID: 36017568."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022;43:280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674; PMID: 34904661. DOI: 10.1093\/eurheartj\/ehab674","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Contaldi C, D\u2019Aniello C, Panico D, et al. Cancer-therapy-related cardiac dysfunction: latest advances in prevention and treatment. Life (Basel) 2025;15:471. https:\/\/doi.org\/10.3390\/life15030471; PMID: 40141815. DOI: 10.3390\/life15030471","DOI":"10.3390\/life15030471"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.050; PMID: 19520246. DOI: 10.1016\/j.jacc.2009.02.050","DOI":"10.1016\/j.jacc.2009.02.050"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Camilli M, Cipolla CM, Dent S, et al. Anthracycline cardiotoxicity in adult cancer patients: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2024;6:655\u201377. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016; PMID: 39479333. DOI: 10.1016\/j.jaccao.2024.07.016","DOI":"10.1016\/j.jaccao.2024.07.016"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mercurio V, Pirozzi F, Lazzarini E, et al. Models of heart failure based on the cardiotoxicity of anticancer drugs. J Card Fail 2016;22:449\u201358. https:\/\/doi.org\/10.1016\/j.cardfail.2016.04.008; PMID: 27103426. DOI: 10.1016\/j.cardfail.2016.04.008","DOI":"10.1016\/j.cardfail.2016.04.008"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ameri P, Canepa M, Anker MS, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 2018;20:879\u201387. https:\/\/doi.org\/10.1002\/ejhf.1165; PMID: 29464808. DOI: 10.1002\/ejhf.1165","DOI":"10.1002\/ejhf.1165"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777; PMID: 25948538. DOI: 10.1161\/CIRCULATIONAHA.114.013777","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lee SH, Cho I, You SC, et al. Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin. Cancers (Basel) 2022;14:2320. https:\/\/doi.org\/10.3390\/cancers14092320; PMID: 35565449. DOI: 10.3390\/cancers14092320","DOI":"10.3390\/cancers14092320"},{"key":"ref13","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400; PMID: 27918725."},{"key":"ref14","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022;23:e333\u2013465. https:\/\/doi.org\/10.1093\/ehjci\/jeac106; PMID: 36017575."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Agunbiade TA, Zaghlol RY, Barac A. Heart failure in relation to tumor-targeted therapies and immunotherapies. Methodist Debakey CardioVasc J 2019;15:250\u20137. https:\/\/doi.org\/10.14797\/mdcj-15-4-250; PMID: 31988685. DOI: 10.14797\/mdcj-15-4-250","DOI":"10.14797\/mdcj-15-4-250"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Seicean S, Seicean A, Alan N, et al. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013;6:420\u20136. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000055; PMID: 23425978. DOI: 10.1161\/CIRCHEARTFAILURE.112.000055","DOI":"10.1161\/CIRCHEARTFAILURE.112.000055"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002;99:8880\u20135. https:\/\/doi.org\/10.1073\/pnas.122249299; PMID: 12072561. DOI: 10.1073\/pnas.122249299","DOI":"10.1073\/pnas.122249299"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 2018;137:e30\u201366. https:\/\/doi.org\/10.1161\/CIR.0000000000000556; PMID: 29437116. DOI: 10.1161\/CIR.0000000000000556","DOI":"10.1161\/CIR.0000000000000556"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 2023;8:262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6; PMID: 37414756. DOI: 10.1038\/s41392-023-01469-6","DOI":"10.1038\/s41392-023-01469-6"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Bloom MW, Vo JB, Rodgers JE, et al. Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail 2025;31:415\u201355. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045; PMID: 39419165. DOI: 10.1016\/j.cardfail.2024.08.045","DOI":"10.1016\/j.cardfail.2024.08.045"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Dobbin SJH, Petrie MC, Myles RC, et al. Cardiotoxic effects of angiogenesis inhibitors. Clin Sci (Lond) 2021;135:71\u2013100. https:\/\/doi.org\/10.1042\/CS20200305; PMID: 33404052. DOI: 10.1042\/CS20200305","DOI":"10.1042\/CS20200305"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ghatalia P, Morgan CJ, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015;94:228\u201337. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.12.008; PMID: 25577572. DOI: 10.1016\/j.critrevonc.2014.12.008","DOI":"10.1016\/j.critrevonc.2014.12.008"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ky B, Vejpongsa P, Yeh ETH, et al. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 2013;113:754\u201364. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.300218; PMID: 23989717. DOI: 10.1161\/CIRCRESAHA.113.300218","DOI":"10.1161\/CIRCRESAHA.113.300218"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"le Noble FAC, Mourad JJ, Levy BI, Struijker-Boudier HAJ. VEGF (vascular endothelial growth factor) Inhibition and hypertension: does microvascular rarefaction play a role? Hypertension 2023;80:901\u201311. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19427; PMID: 36748474. DOI: 10.1161\/HYPERTENSIONAHA.122.19427","DOI":"10.1161\/HYPERTENSIONAHA.122.19427"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Maleki S, Esmaeili Z, Seighali N, et al. Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis. Cardio-Oncology 2024;10:52. https:\/\/doi.org\/10.1186\/s40959-024-00252-y; PMID: 39164789. DOI: 10.1186\/s40959-024-00252-y","DOI":"10.1186\/s40959-024-00252-y"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Koeckerling D, Reddy RK, Barker J, et al. Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis. JAMA Netw Open 2024;7:e2437222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37222; PMID: 39374017. DOI: 10.1001\/jamanetworkopen.2024.37222","DOI":"10.1001\/jamanetworkopen.2024.37222"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lefebvre B, Kang Y, Smith AM, et al. Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol 2020;2:193\u2013203. https:\/\/doi.org\/10.1016\/j.jaccao.2020.04.012; PMID: 32776016. DOI: 10.1016\/j.jaccao.2020.04.012","DOI":"10.1016\/j.jaccao.2020.04.012"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2019;25:e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756; PMID: 30586620. DOI: 10.1016\/j.bbmt.2018.12.756","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Alvi RM, Frigault MJ, Fradley MG, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 2019;74:3099\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.038; PMID: 31856966. DOI: 10.1016\/j.jacc.2019.10.038","DOI":"10.1016\/j.jacc.2019.10.038"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ganatra S, Redd R, Hayek SS, et al. Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation 2020;142:1687\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048100; PMID: 33104402. DOI: 10.1161\/CIRCULATIONAHA.120.048100","DOI":"10.1161\/CIRCULATIONAHA.120.048100"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Gill J. Cardiovascular toxicities with chimeric antigen receptor T-cell therapy. Curr Cardiol Rev 2023;19:e230622206353. https:\/\/doi.org\/10.2174\/1573403X18666220623152350; PMID: 35747980. DOI: 10.2174\/1573403X18666220623152350","DOI":"10.2174\/1573403X18666220623152350"},{"key":"ref32","unstructured":"Tocchetti CG, Farmakis D, Koop Y, et al. Cardiovascular toxicities of immune therapies for cancer \u2013 a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail 2024;26:2055\u201376. https:\/\/doi.org\/10.1002\/ejhf.3340; PMID: 39087551."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Cameron BJ, Gerry AB, Dukes J, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013;5:197ra103. https:\/\/doi.org\/10.1126\/scitranslmed.3006034; PMID: 23926201. DOI: 10.1126\/scitranslmed.3006034","DOI":"10.1126\/scitranslmed.3006034"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1; PMID: 32231332. DOI: 10.1038\/s41569-020-0348-1","DOI":"10.1038\/s41569-020-0348-1"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Sayed A, Munir M, Ghazi SM, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer 2024;12:e008518. https:\/\/doi.org\/10.1136\/jitc-2023-008518; PMID: 38388168. DOI: 10.1136\/jitc-2023-008518","DOI":"10.1136\/jitc-2023-008518"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res 2015;21:4035\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0612; PMID: 26374073. DOI: 10.1158\/1078-0432.CCR-15-0612","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Shan C, Zhang Y, Zhang X, et al. Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma. Sci Rep 2025;15:24782. https:\/\/doi.org\/10.1038\/s41598-025-03391-z; PMID: 40634318. DOI: 10.1038\/s41598-025-03391-z","DOI":"10.1038\/s41598-025-03391-z"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:854\u201368. https:\/\/doi.org\/10.1093\/cvr\/cvz026; PMID: 30715219. DOI: 10.1093\/cvr\/cvz026","DOI":"10.1093\/cvr\/cvz026"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9; PMID: 30442497. DOI: 10.1016\/S1470-2045(18)30608-9","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037; PMID: 29567210. DOI: 10.1016\/S0735-1097(18)31240-3","DOI":"10.1016\/S0735-1097(18)31240-3"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 2018;19:e447\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(18)30457-1; PMID: 30191849. DOI: 10.1016\/S1470-2045(18)30457-1","DOI":"10.1016\/S1470-2045(18)30457-1"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Jain P, Gutierrez Bugarin J, Guha A, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open 2021;6:100252. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100252; PMID: 34461483. DOI: 10.1016\/j.esmoop.2021.100252","DOI":"10.1016\/j.esmoop.2021.100252"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, et al. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol 2024;10:1390\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3065; PMID: 39172480. DOI: 10.1001\/jamaoncol.2024.3065","DOI":"10.1001\/jamaoncol.2024.3065"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Qin Y, Zhang T, Du Z, et al. Prognosis of immune checkpoint inhibitor-related myocarditis: retrospective experience of a single institution. Int Immunopharmacol 2024;136:112385. https:\/\/doi.org\/10.1016\/j.intimp.2024.112385; PMID: 38850788. DOI: 10.1016\/j.intimp.2024.112385","DOI":"10.1016\/j.intimp.2024.112385"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391:933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6; PMID: 29536852. DOI: 10.1016\/S0140-6736(18)30533-6","DOI":"10.1016\/S0140-6736(18)30533-6"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol 2017;70:2552\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1095; PMID: 29145955. DOI: 10.1016\/j.jacc.2017.09.1095","DOI":"10.1016\/j.jacc.2017.09.1095"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J Am Heart Assoc 2021;10:e021686. https:\/\/doi.org\/10.1161\/JAHA.121.021686; PMID: 34482706. DOI: 10.1161\/JAHA.121.021686","DOI":"10.1161\/JAHA.121.021686"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Desai MY, Jellis CL, Kotecha R, et al. Radiation-associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc Imaging 2018;11:1132\u201349. https:\/\/doi.org\/10.1016\/j.jcmg.2018.04.028; PMID: 30092970. DOI: 10.1016\/j.jcmg.2018.04.028","DOI":"10.1016\/j.jcmg.2018.04.028"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Ganatra S, Chatur S, Nohria A. How to diagnose and manage radiation cardiotoxicity. JACC CardioOncol 2020;2:655\u201360. https:\/\/doi.org\/10.1016\/j.jaccao.2020.07.010; PMID: 34396277. DOI: 10.1016\/j.jaccao.2020.07.010","DOI":"10.1016\/j.jaccao.2020.07.010"},{"key":"ref50","unstructured":"Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945\u201360. https:\/\/doi.org\/10.1002\/ejhf.1920; PMID: 32463967."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Li X, Li Y, Zhang T, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res 2020;151:104577. https:\/\/doi.org\/10.1016\/j.phrs.2019.104577; PMID: 31790821. DOI: 10.1016\/j.phrs.2019.104577","DOI":"10.1016\/j.phrs.2019.104577"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Yamaguchi N, Fujii T, Aoi S, et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer 2015;51:2314\u201320. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.031; PMID: 26343314. DOI: 10.1016\/j.ejca.2015.07.031","DOI":"10.1016\/j.ejca.2015.07.031"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2011;58:988\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2011.05.025; PMID: 21851890. DOI: 10.1016\/j.jacc.2011.05.025","DOI":"10.1016\/j.jacc.2011.05.025"},{"key":"ref54","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038; PMID: 34449189."},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190. DOI: 10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium\u2013glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne) 2021;8:777861. https:\/\/doi.org\/10.3389\/fmed.2021.777861; PMID: 34988095. DOI: 10.3389\/fmed.2021.777861","DOI":"10.3389\/fmed.2021.777861"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Lee YH, Lim S, Davies MJ. Cardiometabolic and renal benefits of sodium\u2013glucose cotransporter 2 inhibitors. Nat Rev Endocrinol 2025;21:783\u201398. https:\/\/doi.org\/10.1038\/s41574-025-01170-4; PMID: 40935880. DOI: 10.1038\/s41574-025-01170-4","DOI":"10.1038\/s41574-025-01170-4"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Dabour MS, George MY, Daniel MR, et al. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2024;6:159\u201382. https:\/\/doi.org\/10.1016\/j.jaccao.2024.01.007; PMID: 38774006. DOI: 10.1016\/j.jaccao.2024.01.007","DOI":"10.1016\/j.jaccao.2024.01.007"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Armillotta M, Angeli F, Paolisso P, et al. Cardiovascular therapeutic targets of sodium\u2013glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure. Pharmacol Ther 2025;270:108861. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108861; PMID: 40245989. DOI: 10.1016\/j.pharmthera.2025.108861","DOI":"10.1016\/j.pharmthera.2025.108861"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Wang CY, Chen CC, Lin MH, et al. TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium\u2013glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity. Biology (Basel) 2020;9:369. https:\/\/doi.org\/10.3390\/biology9110369; PMID: 33138323. DOI: 10.3390\/biology9110369","DOI":"10.3390\/biology9110369"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Bar\u0131\u015f V\u00d6, Din\u00e7soy AB, Gedikli E, et al. Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways. Cardiovasc Toxicol 2021;21:747\u201358. https:\/\/doi.org\/10.1007\/s12012-021-09665-y; PMID: 34089496. DOI: 10.1007\/s12012-021-09665-y","DOI":"10.1007\/s12012-021-09665-y"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Yang CC, Chen YT, Wallace CG, et al. Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. Biomed Pharmacother 2019;109:658\u201370. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.095; PMID: 30404073. DOI: 10.1016\/j.biopha.2018.10.095","DOI":"10.1016\/j.biopha.2018.10.095"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci 2022;23:3651. https:\/\/doi.org\/10.3390\/ijms23073651; PMID: 35409011. DOI: 10.3390\/ijms23073651","DOI":"10.3390\/ijms23073651"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 2021;20:150. https:\/\/doi.org\/10.1186\/s12933-021-01346-y; PMID: 34301253. DOI: 10.1186\/s12933-021-01346-y","DOI":"10.1186\/s12933-021-01346-y"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"G\u00f3es-Santos BR, Castro PC, Girardi ACC, et al. Vascular effects of SGLT2 inhibitors: evidence and mechanisms. Am J Physiol Cell Physiol 2025;329:C1150\u201360. https:\/\/doi.org\/10.1152\/ajpcell.00569.2025; PMID: 40908107. DOI: 10.1152\/ajpcell.00569.2025","DOI":"10.1152\/ajpcell.00569.2025"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Tan H, Kareff SA, Krause HB, et al. A pan-tumor description of the genomic, transcriptomic, and immunological landscape of sodium\u2013glucose cotransporter-2 (SGLT2) and association with clinical outcomes. J Clin Oncol 2024;42:104. https:\/\/doi.org\/10.1200\/JCO.2024.42.23_suppl.104. DOI: 10.1200\/JCO.2024.42.23_suppl.104","DOI":"10.1200\/JCO.2024.42.23_suppl.104"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Pandey A, Alcaraz M, Jr., Saggese P, et al. Exploring the role of SGLT2 inhibitors in cancer: mechanisms of action and therapeutic opportunities. Cancers (Basel) 2025;17:466. https:\/\/doi.org\/10.3390\/cancers17030466; PMID: 39941833. DOI: 10.3390\/cancers17030466","DOI":"10.3390\/cancers17030466"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhu J, Yu SJ, et al. Sodium\u2013glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed Pharmacother 2020;132:110821. https:\/\/doi.org\/10.1016\/j.biopha.2020.110821; PMID: 33068934. DOI: 10.1016\/j.biopha.2020.110821","DOI":"10.1016\/j.biopha.2020.110821"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Maurea N, Canale ML, Bisceglia I, et al. Effect of sodium\u2013glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity. J Clin Oncol 2024;42(16_suppl):e24012. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e24012. DOI: 10.1200\/JCO.2024.42.16_suppl.e24012","DOI":"10.1200\/JCO.2024.42.16_suppl.e24012"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Quagliariello V, Canale ML, Bisceglia I, et al. Effect of sodium\u2013glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-\u03baB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. J Clin Oncol 2024;42(16_suppl):e24013. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e24013. DOI: 10.1200\/JCO.2024.42.16_suppl.e24013","DOI":"10.1200\/JCO.2024.42.16_suppl.e24013"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Medina-Hern\u00e1ndez D, C\u00e1diz L, Mastrangelo A, et al. SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics. JACC CardioOncol 2025;7:171\u201384. https:\/\/doi.org\/10.1016\/j.jaccao.2024.12.004; PMID: 39967204. DOI: 10.1016\/j.jaccao.2024.12.004","DOI":"10.1016\/j.jaccao.2024.12.004"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Sabatino J, De Rosa S, Tamm\u00e8 L, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol 2020;19:66. https:\/\/doi.org\/10.1186\/s12933-020-01040-5; PMID: 32414364. DOI: 10.1186\/s12933-020-01040-5","DOI":"10.1186\/s12933-020-01040-5"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Oh CM, Cho S, Jang JY, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J 2019;49:1183\u201395. https:\/\/doi.org\/10.4070\/kcj.2019.0180; PMID: 31456369. DOI: 10.4070\/kcj.2019.0180","DOI":"10.4070\/kcj.2019.0180"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Maurea N, Quagliariello V, Iovine M, et al. Dapagliflozin associated to sacubitril\/valsartan and relationship with cardioprotection in human cardiac cells exposed to doxorubicin and HER2-blocking agents through MyD88, NLRP3 mediated pathways. J Clin Oncol 2022;40:587. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.587. DOI: 10.1200\/JCO.2022.40.16_suppl.587","DOI":"10.1200\/JCO.2022.40.16_suppl.587"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Maurea N, Quagliariello V, De Laurentiis M, et al. The SGLT-2 inhibitor dapagliflozin reduces cell death and apoptosis in cardiomyocytes exposed to trastuzumab and doxorubicin through NLRP3-mediated pathways. J Clin Oncol 2021;39(15_suppl): e15041. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e15041. DOI: 10.1200\/JCO.2021.39.15_suppl.e15041","DOI":"10.1200\/JCO.2021.39.15_suppl.e15041"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Kim D, Jang G, Hwang J, et al. Combined therapy of low-dose angiotensin receptor-neprilysin inhibitor and sodium\u2013glucose Cotransporter-2 inhibitor prevents doxorubicin-induced cardiac dysfunction in rodent model with minimal adverse effects. Pharmaceutics 2022;14:2629. https:\/\/doi.org\/10.3390\/pharmaceutics14122629; PMID: 36559124. DOI: 10.3390\/pharmaceutics14122629","DOI":"10.3390\/pharmaceutics14122629"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Quagliariello V, Di Mauro A, Ferrara G, et al. Cardio-renal and systemic effects of SGLT2i dapagliflozin on short-term anthracycline and HER-2-blocking agent therapy-induced cardiotoxicity. Antioxidants (Basel) 2025;14:612. https:\/\/doi.org\/10.3390\/antiox14050612; PMID: 40427493. DOI: 10.3390\/antiox14050612","DOI":"10.3390\/antiox14050612"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Greco A, Canale ML, Quagliariello V, et al. SGLT2 inhibitors in cancer patients: a comprehensive review of clinical, biochemical, and therapeutic implications in cardio-oncology. Int J Mol Sci 2025;26:4780. https:\/\/doi.org\/10.3390\/ijms26104780; PMID: 40429921. DOI: 10.3390\/ijms26104780","DOI":"10.3390\/ijms26104780"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Ren C, Sun K, Zhang Y, et al. Sodium\u2013glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front Pharmacol 2021;12:664181. https:\/\/doi.org\/10.3389\/fphar.2021.664181; PMID: 33995090. DOI: 10.3389\/fphar.2021.664181","DOI":"10.3389\/fphar.2021.664181"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium\u2013glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail 2022;10:559\u201367. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006; PMID: 35902159. DOI: 10.1016\/j.jchf.2022.03.006","DOI":"10.1016\/j.jchf.2022.03.006"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Abdel-Qadir H, Carrasco R, Austin PC, et al. The association of sodium\u2013glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC CardioOncol 2023;5:318\u201328. https:\/\/doi.org\/10.1016\/j.jaccao.2023.03.011; PMID: 37397088. DOI: 10.1016\/j.jaccao.2023.03.011","DOI":"10.1016\/j.jaccao.2023.03.011"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Hwang HJ, Kim M, Jun JE, Yon DK. Sodium\u2013glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea. Sci Rep 2023;13:21756. https:\/\/doi.org\/10.1038\/s41598-023-48678-1; PMID: 38066029. DOI: 10.1038\/s41598-023-48678-1","DOI":"10.1038\/s41598-023-48678-1"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Fath AR, Aglan M, Aglan A, et al. Cardioprotective potential of sodium\u2013glucose Cotransporter-2 inhibitors in patients with cancer treated with anthracyclines: an observational study. Am J Cardiol 2024;222:175\u201382. https:\/\/doi.org\/10.1016\/j.amjcard.2024.04.032; PMID: 38692401. DOI: 10.1016\/j.amjcard.2024.04.032","DOI":"10.1016\/j.amjcard.2024.04.032"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Perelman MG, Brzezinski RY, Waissengrin B, et al. Sodium\u2013glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardio-Oncology 2024;10:2. https:\/\/doi.org\/10.1186\/s40959-023-00199-6; PMID: 38212825. DOI: 10.1186\/s40959-023-00199-6","DOI":"10.1186\/s40959-023-00199-6"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Bhatti AW, Patel R, Dani SS, et al. SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes. JACC CardioOncol 2024;6:863\u201375. https:\/\/doi.org\/10.1016\/j.jaccao.2024.08.001; PMID: 39801650. DOI: 10.1016\/j.jaccao.2024.08.001","DOI":"10.1016\/j.jaccao.2024.08.001"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Bhalraam U, Veerni RB, Paddock S, et al. Impact of sodium\u2013glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prev Cardiol 2026;33:214\u201326. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf026; PMID: 40044419. DOI: 10.1093\/eurjpc\/zwaf026","DOI":"10.1093\/eurjpc\/zwaf026"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Yan Z, Xing X, Huang J. The influence of sodium\u2013glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: a meta-analysis. Biomol Biomed 2025;25:1723\u201336. https:\/\/doi.org\/10.17305\/bb.2025.11847; PMID: 40079223. DOI: 10.17305\/bb.2025.11847","DOI":"10.17305\/bb.2025.11847"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"V\u00e1squez-Tirado GA, Meregildo-Rodr\u00edguez ED, Quispe-Casta\u00f1eda CV, et al. Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD. Naunyn Schmiedebergs Arch Pharmacol 2025;399:1197\u2013210. https:\/\/doi.org\/10.1007\/s00210-025-04489-x; PMID: 40748473. DOI: 10.1007\/s00210-025-04489-x","DOI":"10.1007\/s00210-025-04489-x"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. JACC Heart Fail 2024;12:67\u201378. https:\/\/doi.org\/10.1016\/j.jchf.2023.08.026; PMID: 37897456. DOI: 10.1016\/j.jchf.2023.08.026","DOI":"10.1016\/j.jchf.2023.08.026"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Daniele AJ, Gregorietti V, Costa D, L\u00f3pez-Fern\u00e1ndez T. Use of empagliflozin in the prevention of cardiotoxicity: the EMPACARD \u2013 PILOT trial. Cardio-Oncology 2024;10:58. https:\/\/doi.org\/10.1186\/s40959-024-00260-y; PMID: 39237985. DOI: 10.1186\/s40959-024-00260-y","DOI":"10.1186\/s40959-024-00260-y"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Kamphuis JAM, Linschoten M, Cramer MJ, et al. Cancer therapy-related cardiac dysfunction of nonanthracycline chemotherapeutics: what is the evidence? JACC CardioOncol 2019;1:280\u201390. https:\/\/doi.org\/10.1016\/j.jaccao.2019.09.007; PMID: 34396190. DOI: 10.1016\/j.jaccao.2019.09.007","DOI":"10.1016\/j.jaccao.2019.09.007"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 2018;10:1758835918780140. https:\/\/doi.org\/10.1177\/1758835918780140; PMID: 29977352. DOI: 10.1177\/1758835918780140","DOI":"10.1177\/1758835918780140"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev 2018;26:122\u20139. https:\/\/doi.org\/10.1097\/CRD.0000000000000183; PMID: 29077585. DOI: 10.1097\/CRD.0000000000000183","DOI":"10.1097\/CRD.0000000000000183"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Curl CL, Delbridge LMD, Canny BJ, Wendt IR. Testosterone modulates cardiomyocyte Ca(2+) handling and contractile function. Physiol Res 2009;58:293\u20137. https:\/\/doi.org\/10.33549\/physiolres.931460; PMID: 18380535. DOI: 10.33549\/physiolres.931460","DOI":"10.33549\/physiolres.931460"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Chen DY, Lee CH, Tsai ML, et al. Cancer therapy-related cardiac dysfunction in patients with prostate cancer undergoing androgen deprivation therapy. J Am Heart Assoc 2023;12:e030447. https:\/\/doi.org\/10.1161\/JAHA.123.030447; PMID: 37750600. DOI: 10.1161\/JAHA.123.030447","DOI":"10.1161\/JAHA.123.030447"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Cheung YM, Ramchand SK, Yeo B, Grossmann M. Cardiometabolic effects of endocrine treatment of estrogen receptor-positive early breast cancer. J Endocr Soc 2019;3:1283\u2013301. https:\/\/doi.org\/10.1210\/js.2019-00096; PMID: 31259291. DOI: 10.1210\/js.2019-00096","DOI":"10.1210\/js.2019-00096"},{"key":"ref97","unstructured":"Breast International Group (BIG) 1-98 Collaborative Group, Th\u00fcrlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747\u201357. https:\/\/doi.org\/10.1056\/NEJMoa052258; PMID: 16382061."}],"container-title":["US Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2025.20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:34:49Z","timestamp":1786030489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2025.20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":98,"URL":"https:\/\/doi.org\/10.15420\/usc.2025.20","relation":{},"ISSN":["1758-3896","1758-390X"],"issn-type":[{"value":"1758-3896","type":"print"},{"value":"1758-390X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"e14"}}